<DOC>
	<DOCNO>NCT02286843</DOCNO>
	<brief_summary>Some breast cancer cell make protein call Human Epidermal Growth factor receptor 2 ( HER2 ) . Patients HER2 positive ( HER2+ ) breast cancer receive medicine attack HER2 , help patient live long . Some HER2 negative ( HER2- ) breast cancer patient also benefit medicine attack HER2 , know patient benefit . This study use new image method , 89Zr-trastuzumab PET/CT , identify patient may benefit medicine attack HER2 . This experimental .</brief_summary>
	<brief_title>Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases , Which Are Amenable HER2 Targeted Therapy ?</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women age &gt; 18 Biopsy proven HER2 negative primary breast cancer biopsy proven metastatic disease . 5 focus demonstrable metastasis recent image modality ( CT , MR , FDG PET/CT ) ECOG performance score 02 Life expectancy &lt; 3months Pregnancy lactation Patients undergo PET/CT scan weight limit CNS disease recent imaging</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>89Zr-trastuzumab</keyword>
	<keyword>PET/CT</keyword>
	<keyword>14-156</keyword>
</DOC>